Curis, Inc.: Revision history

19 August 2022

• curprev 19:3719:37, 19 August 2022 95.149.241.133 talk 1,421 bytes +11 No edit summary undo

12 August 2022

• curprev 14:2414:24, 12 August 2022 109.180.50.163 talk 1,410 bytes +15 No edit summary undo

27 July 2022

• curprev 19:3719:37, 27 July 2022 >Chris 1,395 bytes +1,395 Created page with "Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor..."